References
- Campbell JD, Kaló Z. Fair global drug pricing. Expert Rev Pharmacoecon Outcomes Res. 2018 Nov 02;18(6):581–583.
- Inotai A, Kaló Z. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? – the good, the bad, and the ugly ways. Expert Rev Pharmacoecon Outcomes Res. 2019 Nov 02;19(6):627–632.
- Scalo JF, Rascati KL. Trends and issues in oncology costs. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb 01;14(1):35–44.
- Vogler S. Can we achieve affordable cancer medicine prices? Developing a pathway for change. Expert Rev Pharmacoecon Outcomes Res. 2021;321–325. doi: 10.1080/14737167.2021.1898951
- Vogler S Payer policies to support innovation and access to medicines in the WHO European Region. Copenhagen: World Health Organization. Regional Office for Europe; 2022. Available from: https://apps.who.int/iris/handle/10665/361753 (accessed 28 Jan 2023)
- Janzic U, Knez L, Janzic A, et al. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of clinical benefit scale in slovenia. Expert Rev Pharmacoecon Outcomes Res. 2019 Nov 02;19(6):717–723.
- Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ (Clin Res Ed). 2017;359:j4530. doi: 10.1136/bmj.j4530
- Hwang TJ, Ross JS, Vokinger KN, et al. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. BMJ (Clin Res Ed). 2020;371:m3434. doi: 10.1136/bmj.m3434
- Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):23–29. doi: 10.1586/erp.11.95
- Peppercorn J. The financial burden of cancer care: do patients in the US know what to expect? Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):835–842. doi: 10.1586/14737167.2014.963558
- Kaló Z, Alabbadi I, Al Ahdab OG, et al. Implications of external price referencing of pharmaceuticals in Middle East countries. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):993–998. doi: 10.1586/14737167.2015.1048227
- Kalo Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries [Review]. Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):735–741. doi: 10.1586/14737167.2013.847367
- Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s. Health Econ. 2005;14(3):269–292. doi: 10.1002/hec.931
- Kyle MK. Pharmaceutical price controls and entry strategies. Rev Econ Stat. 2007;89(1):88–99. doi: 10.1162/rest.89.1.88
- Vogler S, Schneider P, Zimmermann N. Evolution of average European medicine prices: implications for the methodology of external price referencing. PharmacoEconomics Open. 2019;3(3):303–309. doi: 10.1007/s41669-019-0120-9
- Chapman S, Dedet G, Lopert R Shortages of medicines in OECD countries. OECD health working papers. Paris: Organisation for Economic Co-operation and Development; 2022. Available from: https://www.oecd-ilibrary.org/content/paper/b5d9e15d-en (accessed 26 Mar 2023)
- Vis C, Pelsy F, Dijkstal F, et al. Future-proofing pharmaceutical legislation: study on medicine shortages: final report. Brussels: European Commission Directorate-General for Health Food Safety, Publications Office; 2021. Available from: https://www.oecd-Ilibrary.org/content/paper/b5d9e15d-en (accessed 15 Mar 2023)
- Vogler S, Zimmermann N, Haasis MA PPRI Report 2018: Pharmaceutical pricing and reimbursement policies in 47 PPRI network member countries Vienna: WHO Collaborating Centre for Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (GÖG/Austrian National Public Health Institute); 2019
- Vogler S, Haasis MA, Dedet G, et al. Medicines Reimbursement Policies in Europe. World Health Organization Office for Europe. Copenhagen 2018. Available from https://www.who.int/europe/publications/i/item/9789289053365 (accessed 15 Mar 2023)
- Vogler S, Habl C, Leopold C, et al. PHIS Hospital Pharma Report. Vienna: Pharmaceutical Health Information System (PHIS); 2010. Available from: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PHIS_Hospital%20Pharma_Report_2.pdf (accessed 4 Jan 2022).
- Vogler S, Zimmermann N, Habl C, et al. The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. Cost Eff Resour Allocation. 2013;11(1):15. doi: 10.1186/1478-7547-11-15
- Vogler S, Zimmermann N, Leopold C, et al. Discounts and rebates granted for medicines for hospital use in five European countries. PharmacoEconomics. 2013;5(1):1–10. doi: 10.2174/1876824520130426001
- Perelman J, Duarte-Ramos F, Melo Gouveia A, et al. How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021. Expert Rev Pharmacoecon Outcomes Res. 2023;23(1):99–109. doi: 10.1080/14737167.2023.2146579
- Simoens S. How do biosimilars sustain value, affordability, and access to oncology care? Expert Review Of Pharmacoeconomics & Outcomes Research. 2020;327–329. doi: 10.1080/14737167.2020.1813570 21 3
- Manova M, Savova A, Vasileva M, et al. Comparative price analysis of biological products for treatment of rheumatoid arthritis. Front Pharmacol. 2018 Sep 20;9. doi: 10.3389/fphar.2018.01070
- Vogler S, Zimmermann N, Wirtz VJ. Policy cooperation and interface issues. J Pharm Policy Pract. 2015;8(S1):E3. doi: 10.1186/2052-3211-8-S1-E3
- WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Copenhagen: World Health Organization Regional Office for Europe; 2015. Available from: https://apps.who.int/iris/handle/10665/159405 (accessed 20 Apr 2023)
- Vogler S, Paris V, Panteli D, Ensuring access to medicines: how to redesign pricing, reimbursement and procurement?, in European Observatory on Health Care Systems, editor. Policy Brief and Summaries. Copenhagen: WHO Regional Office for Europe; 2018. Available from: http://www.euro.who.int/__data/assets/pdf_file/0009/379710/PolicyBrief_AUSTRIA_PB30_web_13082018.pdf (accessed 25 Oct 2022)
- Vogler S, Paris V, Ferrario A, et al. How can pricing and reimbursement policies improve affordable access to medicines? lessons learned from European Countries. Appl Health Econ Health Policy. 2017;15(3):307–321. doi: 10.1007/s40258-016-0300-z
- WHO. WHO Guideline On Country Pharmaceutical Pricing Policies. Second edition. Geneva: World Health Organization; 2020. Available from: https://apps.who.int/iris/rest/bitstreams/1309649/retrieve (accessed 4 Jan 2023)
- Vogler S, Zimmermann N, Habl C, et al. OHP-073 survey of interface management measures regarding medicines. Eur J Hosp Pharm Sci Pract. 2013;20(Suppl 1):A161–A. doi: 10.1136/ejhpharm-2013-000276.446
- Björkhem-Bergman L, Andersén-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol. 2013;69(S1):73–78. doi: 10.1007/s00228-013-1497-5
- Vogler S, Leopold C, Zimmermann N, et al. The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative—Experiences from engaging with pharmaceutical policy makers. Health Policy Technol. 2014;3(2):139–148. doi: 10.1016/j.hlpt.2014.01.001
- Vogler S, Salcher-Konrad M, Habimana K Study on best practices in the public procurement of medicines: final report. Brussels: European Commission, European Health and Digital Executive Agency, Publications Office of the European Union; 2022. Available from: https://data.europa.eu/doi/10.2925/044781 (accessed 20 Apr 2023).
- WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Glossary of pharmaceutical terms. Vienna: Gesundheit Österreich (GÖG/Austrian National Public Health Institute); 2023. Available from: https://ppri.goeg.at/ppri-glossary (accessed 13 Mar 2023).
- Matusewicz W, Godman B, Pedersen HB, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–758. doi: 10.1586/14737167.2015.1085803
- Herms S, Rutledge P. The Lothian Joint Formulary: overcoming the barriers to formulary success. Pharmacy In Practice. 2002;12:279–285.
- Gustafsson LL, Wettermark B, Godman B, et al. The ‘wise list’- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011 Apr;108(4):224–233.
- Eriksen J, Gustafsson LL, Ateva K, et al. High adherence to the ‘Wise List’ treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ Open. 2017;7(4):e014345. doi: 10.1136/bmjopen-2016-014345
- Weise N, Festoy H, Hagen C, et al. PPRI Pharma Profile: Norway 2018. Vienna: Pharmaceutical Pricing and Reimbursement Information (PPRI); 2018. Available from: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PPRI%20Norway%202018.pdf (accessed 20 Jun 2022)
- Aure OH, Festoy H PPRI Pharma Profile: Norway 2022. Vienna: Pharmaceutical Pricing and Reimbursement Information (PPRI); 2022. Available from: https://ppri.goeg.at/system/files/inline-files/PPRINorway2022_final.pdf (accessed 20 Jan 2023)
- Storms H, Schreurs M PHIS Pharma Profile: the Netherlands. Vienna: Pharmaceutical Health Information System (PHIS); 2010. Available from: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PHIS%20NL%20Hospital%20Pharma%20Report%202009_5.pdf (accessed 2 Feb 2023)
- Federal Ministry of Health, Main Association of the Austrian Social Health Insurance institutions, Austrian provinces. Zielsteuerungsvertrag auf Bundesebene. Zielsteuerung-Gesundheit 2013-2016 (Target control agreement at federal level. Target Control - Health 2013-2016). Vienna 2013. Available from: https://www.parlament.gv.at/PAKT/VHG/XXV/III/III_00038/imfname_336346.pdf (accessed 13 Jan 2022)
- Vogler S, Bauer E, Habimana K. Centralised pharmaceutical procurement: learnings from six European Countries. Appl Health Econ Health Pol. 2022;20(5):637–650. doi: 10.1007/s40258-022-00729-w
- Vogler S, Habimana K, Bauer E, et al. Centralised procurement of medicines in Portugal – Final Report. Vienna: Gesundheit Österreich; 2021. Avallable from: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/GOe_FP_PT_CPM_Full%20Report_total_bf.pdf (accessed 15 Apr 2023)
- ACM. Drug manufacturer Pfizer to discontinue its steering pricing structure for Enbrel following discussions with ACM. Authority for Consumers & Markets; 2022. Available from: https://www.acm.nl/en/publications/drug-manufacturer-pfizer-discontinue-its-steering-pricing-structure-enbrel-following-discussions-acm#:~:text=discussions%20with%20ACM-,Drug%20manufacturer%20Pfizer%20to%20discontinue%20its%20steering%20pricing%20structure%20for,Enbrel%20through%20its%20discount%20schemes (accessed 12 Mar 2023)
- Biosimilar Development. The competition council sanctioned roche Romania with fines of 128 million Euro. 2020. Available from: https://www.biosimilardevelopment.com/doc/the-competition-council-sanctioned-roche-romania-with-fines-of-million-euro-0001 (accessed 8 Apr 2023)
- AFMPS. Circulaire No. 646: À l’attention des hopitaux, des officines hospitalières, des fabricants et distributeurs en gros de médicaments et des fabricants importateurs et distributeurs de dispositifs médicaux [Circular No. 646: To the attention of hospitals, hospital pharmacies. In: Manufacturers and wholesale distributors of drugs and manufacturers importing and distributing medical devices]. Brussels: agence fédérale des médicaments et des produits de santé. 2019. Available from (accessed 26 Mar 2023 https://www.afmps.be/sites/default/files/content/DC-CT/20190625151638.pdf
- Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2017;19(1):1–30. doi: 10.1007/s10198-017-0871-0
- Sekretariatet for nye metoder. Nye Metoder. 2021. Available from: https://nyemetoder.no/english (accessed 29 Mar 2023)
- Vogler S. Gratulation mit Wunschliste - Europäischer Blick aus dem Nachbarland [Congratulation and a wish list. European viewpoint from the neighbouring country]. In: Greiner W, Witte J Gensorowsky D, editors. et al. AMNOG-Report 2020. 10 Jahre AMNOG - Rückblick und Ausblick [AMNOG report 2020. 10 years AMNOG – Looking back and looking forward]. Hamburg: DAK-Gesundheit; 2020. (accessed 15 Mar 2023. Available from: https://www.dak.de/dak/download/report-2335144.pdf
- James D, Kullman D PHIS Hospital Pharma Report: United Kingdom. Vienna: Pharmaceutical Health Information System (PHIS); 2009. Available from: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PHIS%20Pharma%20Profile%20UK%20Feb2011_5.pdf (accessed 13 Mar 2023)
- Zimmermann N, Vogler S PHIS Hospital Pharma Report: Austria. Vienna: Pharmaceutical Health Information System (PHIS); 2009. Available from: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PHIS_Hospital_Pharma_AT_Report_Final_version_090630_6.pdf (accessed 13 Mar 2023)
- Simoens S, Spinewine A, Foulon V, et al. Review of the cost-effectiveness of interventions to improve seamless care focusing on medication. Int J Clin Pharm. 2011;33(6):909–917. doi: 10.1007/s11096-011-9563-5.
- Belloni A, Morgan D, Paris V. Pharmaceutical Expenditure and Policies. Paris: Organisation for Economic Cooperiaton and Development; 2016.
- Vogler S, Zimmermann N, Mazag J. Procuring medicines in hospitals: results of the European PHIS survey. EJHP Practice. 2011;17:20–21.
- Vogler S. Pharmaceutical regulation and policies in Austria. Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde. 2022;13(1):639. doi: 10.30968/rbfhss.2022.131.0639
- Dranitsaris G, Zhu X, Adunlin G, et al. Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs. Expert Rev Pharmacoecon Outcomes Res. 2018 Jul 04;18(4):351–357.
- Quinn C, Ciarametaro M, Sils B, et al. Medicaid best price reforms to enable innovative payment models for cell and gene therapies. Expert Rev Pharmacoecon Outcomes Res. 2023 Feb 07;23(2):191–203.
- Gallini A, Legal R, Taboulet F. The influence of drug use in university hospitals on the pharmaceutical consumption in their surrounding communities. Br J Clin Pharmacol. 2012;7:1365–2125.
- European Medicines Agency, Heads of Medicines Agencies. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. Amsterdam: EMA; 2022. Available from: https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf (accessed 26 Apr 2023)
- WHO. Indicators for monitoring national drug policies. A practical manual. 2nd Edition. Geneva: World Health Organization; 1999. Available from: https://apps.who.int/iris/handle/10665/60706 (accessed 29 Apr 2023)
- Vogler S Access to information in markets for medicines in the WHO European Region. Oslo Medicines Initiative technical report. Copenhagen: World Health Organization. Regional Office for Europe; 2022. Available from: https://apps.who.int/iris/rest/bitstreams/1462628/retrieve (accessed 16 Nov 2022)
- Spinewine A, Foulon V, Claeys C, et al. Seamless care focusing on medication between hospital and home. Brussels: Belgian Health Care Knowledge Centre (KCE); 2010. Available from: https://kce.fgov.be/sites/default/files/atoms/files/kce_131c_seamless_care.pdf (accessed 21 Apr 2023).
- Naci H, Salcher-Konrad M, Kesselheim AS, et al. Generating comparative evidence on new drugs and devices before approval. Lancet. 2020;395(10228):986–997. doi: 10.1016/S0140-6736(19)33178-2
- Panteli D, Eckhardt H, Nolting A, et al. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Res Policy Syst. 2015;13(1):39. doi: 10.1186/s12961-015-0028-5
- Vogler S, Haasis MA, van den Ham R, et al. Cross-Country Collaborations to improve access to medicines and vaccines in the WHO European Region. World Health Organization Regional Office for Europe; 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/332933/9789289055031-eng.pdf (accessed 8 May 2022)
- Malmstrom R, Godman B, Diogene E, et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4. doi: 10.3389/fphar.2013.00039.
- Vogler S. “Ready for the future?”–Status of national and cross-country horizon scanning systems for medicines in European countries. GMS Ger Med Sci. 2022;22:Doc05.
- WHO/Europe. Better access to effective, novel and affordable medicines: a new vision for collaboration between the public and private sector. Regional Committee For Europe EUR/RC70/Inf.Doc./6, 70th Session. Virtual Session, p. 14–15 Sep 2020. Copenhagen: World Health Organization Regional Office for Europe; 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/334171/70id06e-AccessMed-200722.pdf?sequence=1&isAllowed=y (accessed 5 Feb 2023)
- European Commission. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions. Pharmaceutical Strategy For Europe. COM/2020/761 Final. 25 Nov 2020p. Brussels2020. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52020DC0761 (accessed 17 Jan 2023)
- Vogler S, Zimmermann N, Babar Z-U-D, et al. Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. Journal of Pharmaceutical Policy and Practice, Vienna. 2021/Jan/25;14:p. 18.
- Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU. Brussels 2021. Available from: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R2282 (accessed 8 Apr 2023)